Inspire Medical price target lowered to $100 from $140 at Stifel

Stifel analyst Jonathan Block lowered the firm’s price target on Inspire Medical (INSP) to $100 from $140 and keeps a Hold rating on the shares. The firm, which says its previously expressed GLP-1 concern is playing out, tells investors that a “couple of our key Inspire Medical concerns have taken hold,” adding that it believes inventory “could be the next shoe to drop.”